J. Brice Weinberg

Dr. J. Brice Weinberg

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
CDChristabelle J Darcy
Christabelle J Darcy
GMGabriela Minigo
Gabriela Minigo
KPKim A Piera
Kim A Piera
JDJoshua S Davis
Joshua S Davis
YMYvette R McNeil
Yvette R McNeil
TWTonia Woodberry
Tonia Woodberry
Introduction: Impaired T cell function in sepsis is associated with poor outcome, but the mechanisms are unclear. In cancer, arginase-expressing myeloid derived suppressor cells (MDSCs) deplete arginine, impair T cell receptor CD3 zeta-chain expression and T cell function and are linked to poor clinical outcome, but their role during acute human infectious disease and in particular sepsis remains unknown. Hypoarginemia is prevalent in sepsis. This study aimed to determine whether neutrophils that co-purify with PBMC express arginase, and if arginine depletion constrains T cell CD3 zeta-chain expression and function in human sepsis. Methods: Using flow cytometry, cell culture, HPLC, arginase activity and mRNA detection, our study examined whether neutrophils, with reduced buoyant density isolated in the Ficoll interface, metabolise L-arginine and suppress T cell proliferation in sepsis. A total of 35 sepsis patients (23 with septic shock) and 12 hospital controls in a tertiary referral hospital in tropical Australia were evaluated. Results: Only sepsis patients had interphase neutrophils, neutrophils co-purifying with mononuclear cells (≤1.077 specific gravity). The percentage of interphase neutrophils in sepsis was proportional to sepsis severity and correlated with plasma IL-6 concentrations. Ex vivo, sepsis-derived interphase neutrophils expressed arginase, metabolised culture L-arginine and suppressed T cell proliferation and CD3 zeta-chain expression. In vivo, in septic shock there was a longitudinal inverse association between interphase neutrophil number and CD3 zeta-chain expression. Depletion or inhibition of interphase neutrophils in vitro restored zeta-chain expression and T cell function. Conclusions: For the first time during an acute human infection, interphase neutrophils that express arginase were found to circulate in sepsis, in proportion to disease severity. These neutrophil-MDSCs impair T cell CD3 zeta-chain expression and T cell function via L-arginine metabolism, and likely contribute to the T cell dysfunction seen in sepsis. Modulation of neutrophil-MDSC or their downstream effects warrant consideration as targets for novel adjunctive therapies in sepsis.

15 September 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
PSPeter J. Siska
Peter J. Siska
GWGerritje J. W. van der Windt
Gerritje J. W. van der Windt
RKRigel J. Kishton
Rigel J. Kishton
SCSivan Cohen
Sivan Cohen
WEWilliam Eisner
William Eisner
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
Leukemia can promote T cell dysfunction and exhaustion that contributes to increased susceptibility to infection and mortality. The treatment-independent mechanisms that mediate leukemia-associated T cell impairments are poorly understood, but metabolism tightly regulates T cell function and may contribute. In this study, we show that B cell leukemia causes T cells to become activated and hyporesponsive with increased PD-1 and TIM3 expression similar to exhausted T cells and that T cells from leukemic hosts become metabolically impaired. Metabolic defects included reduced Akt/mammalian target of rapamycin complex 1 (mTORC1) signaling, decreased expression of the glucose transporter Glut1 and hexokinase 2, and reduced glucose uptake. These metabolic changes correlated with increased regulatory T cell frequency and expression of PD-L1 and Gal-9 on both leukemic and stromal cells in the leukemic microenvironment. PD-1, however, was not sufficient to drive T cell impairment, as in vivo and in vitro anti–PD-1 blockade on its own only modestly improved T cell function. Importantly, impaired T cell metabolism directly contributed to dysfunction, as a rescue of T cell metabolism by genetically increasing Akt/mTORC1 signaling or expression of Glut1 partially restored T cell function. Enforced Akt/mTORC1 signaling also decreased expression of inhibitory receptors TIM3 and PD-1, as well as partially improved antileukemia immunity. Similar findings were obtained in T cells from patients with acute or chronic B cell leukemia, which were also metabolically exhausted and had defective Akt/mTORC1 signaling, reduced expression of Glut1 and hexokinase 2, and decreased glucose metabolism. Thus, B cell leukemia–induced inhibition of T cell Akt/mTORC1 signaling and glucose metabolism drives T cell dysfunction.

1 October 2008 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
JWJ. Brice Weinberg
J. Brice Weinberg
BLBert K Lopansri
Bert K Lopansri
EMEsther Mwaikambo
Esther Mwaikambo
DGDonald L Granger
Donald L Granger
Purpose of review Parasiticidal therapy of severe falciparum malaria improves outcome, but up to 30% of these patients die despite best therapy. Nitric oxide is protective against severe disease, and both nitric oxide and arginine (the substrate for nitric oxide synthase) are low in clinical malaria. Parasitized red blood cell interactions with endothelium are important in the pathophysiology of malaria. This review describes new information regarding nitric oxide, arginine, carbon monoxide, and endothelial function in malaria. Recent findings Low arginine, low nitric oxide production, and endothelial dysfunction are common in severe malaria. The degree of hypoargininemia and endothelial dysfunction (measured by reactive hyperemia–peripheral artery tonometry) is proportional to parasite burden and severity of illness. Plasma arginase (an enzyme that catabolizes arginine) is elevated in severe malaria. Administering arginine intravenously reverses hypoargininemia and endothelial dysfunction. The cause(s) of hypoargininemia in malaria is unknown. Carbon monoxide (which shares certain functional properties with nitric oxide) protects against cerebral malaria in mice. Summary Replenishment of arginine and restoration of nitric oxide production in clinical malaria should diminish parasitized red blood cells adherence to endothelium and reduce the sequelae of these interactions (e.g. cerebral malaria). Arginine therapy given in addition to conventional antimalaria treatment may prove to be beneficial in severe malaria.

1 June 2009 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
JWJ. Brice Weinberg
J. Brice Weinberg
YCYouwei Chen
Youwei Chen
NJNing Jiang
Ning Jiang
BBBethany E. Beasley
Bethany E. Beasley
JSJohn C. Salerno
John C. Salerno
DGDipak K. Ghosh
Dipak K. Ghosh

1 November 2007 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
JWJ. Brice Weinberg
J. Brice Weinberg
AVAlicia D. Volkheimer
Alicia D. Volkheimer
YCYouwei Chen
Youwei Chen
BBBethany E. Beasley
Bethany E. Beasley
NJNing Jiang
Ning Jiang
MLMarc C. Levesque
Marc C. Levesque
Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgVH) mutation status, cytogenetic abnormalities, and leukemia cell CD38 and Zap‐70 to older, traditional parameters. We also wanted to construct a simple, inexpensive prognosis score that would significantly predict TTT and survival in patients at the time of diagnosis and help practicing clinicians. In univariate analyses, patients with higher clinical stage, higher leukocyte count at diagnosis, shorter leukocyte doubling time, elevated serum lactate dehydrogenase (LDH), unmutated immunoglobulin heavy chain variable region (IgVH) genes, and higher CD38 had a shorter overall survival and time‐to‐treatment (TTT). CLL cell Zap‐70 expression was higher in patients with unmutated IgVH, and those with higher Zap‐70 tended to have shorter survival. IgVH4‐34 or IgVH1‐69 was the most common IgVH genes used (16 and 12%, respectively). Of those with IgVH1‐69, 86% had unmutated IgVH and had a significantly shorter TTT. A cytogenetic abnormality was noted in 71% of the patients tested. Patients with 11q22 del and 17p13 del or complex abnormalities were significantly more likely to have unmutated IgVH. We found that a prognostic score constructed using modified Rai stage, cellular CD38, and serum LDH (parameters easily obtained clinically) significantly predicted TTT and survival in patients at the time of diagnosis and performed as well or better than models using the newer markers. Am. J. Hematol., 2007.

7 July 2016 in Scientific Reports
Verified
Journal Article
Open access
JWJ. Brice Weinberg
J. Brice Weinberg
AVAlicia D. Volkheimer
Alicia D. Volkheimer
MRMatthew P. Rubach
Matthew P. Rubach
SFSalvatore M. Florence
Salvatore M. Florence
JMJackson P. Mukemba
Jackson P. Mukemba
EMEsther D. Mwaikambo
Esther D. Mwaikambo
We earlier established that nitric oxide (NO) is protective against severe malaria and that arginine and NO levels are reduced in malaria patients. We now show that an M2-like blood monocyte phenotype is significantly associated with hypoargininemia, NO insufficiency, and disease severity in Tanzanian children with falciparum malaria. Compared to control children (n = 106), children with moderately severe (n = 77) and severe falciparum malaria (n = 129) had significantly higher mononuclear cell arginase 1 mRNA, protein, and enzyme activity; lower NOS2 mRNA; lower plasma arginine; and higher plasma IL-10, IL-13, and IL-4. In addition, monocyte CD206 and CD163 and plasma soluble CD163 were elevated. Multivariate logistic regression analysis revealed a significant correlation of risk of severe malaria with both plasma IL-10 and soluble CD163 levels. Monocyte M2 skewing likely contributes to NO bioinsufficiency in falciparum malaria in children. Treatments that reverse the M2 polarization may have potential as adjunctive treatment for malaria.